1 January 2024 v2025.59.1 limited_company_frs_102_section_1a_v1_1_2 companies_houseSoftwarefalsetruetruetrueNo description of principal activityfalsexbrli:purexbrli:sharesiso4217:GBP144023152024-01-012024-12-31144023152024-12-3114402315bus:Director12024-01-012024-12-3114402315bus:Director22024-01-012024-12-3114402315bus:Director32024-01-012024-12-3114402315bus:Director32024-12-3114402315bus:RegisteredOffice2024-01-012024-12-31144023152022-10-062023-12-31144023152023-12-3114402315core:WithinOneYear2024-12-3114402315core:WithinOneYear2023-12-3114402315core:ShareCapital2024-12-3114402315core:ShareCapital2023-12-3114402315core:RetainedEarningsAccumulatedLosses2024-12-3114402315core:RetainedEarningsAccumulatedLosses2023-12-3114402315core:RetainedEarningsAccumulatedLosses2022-10-062023-12-3114402315core:ShareCapital2022-10-062023-12-3114402315core:ShareCapital2024-01-0114402315core:RetainedEarningsAccumulatedLosses2024-01-01144023152024-01-0114402315core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3114402315core:OfficeEquipment2024-01-012024-12-3114402315core:PlantMachinery2024-12-3114402315core:PlantMachinery2024-01-0114402315core:PlantMachinery2024-01-012024-12-3114402315core:PlantMachinery2023-12-3114402315core:CostValuation2024-01-0114402315core:AdditionsToInvestments2024-12-3114402315core:DisposalsRepaymentsInvestments2024-12-3114402315core:CostValuation2024-12-311440231512024-01-012024-12-3114402315countries:EnglandWales2024-01-012024-12-3114402315bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3114402315bus:PrivateLimitedCompanyLtd2024-01-012024-12-3114402315bus:SmallEntities2024-01-012024-12-3114402315bus:FullAccounts2024-01-012024-12-31
Company registration number:
14402315
Omnia Health Group Limited
Unaudited Financial Statements for the year ended
31 December 2024
Omnia Health Group Limited
Officers and Professional Advisers
Year ended
31 December 2024
Directors
H Mehmet-Quirk
M Quirk
M Chapman
(resigned
1 February 2024
)
Registered office
2nd Floor 10 Charles Ii Street
London
SW1Y 4AA
England
Omnia Health Group Limited
Directors' Report
Year ended
31 December 2024
The directors present their report and the unaudited
financial statements
of the company for the year ended 31 December 2024.

Change of company name

Directors

The directors who served the company during the year were as follows:
H Mehmet-Quirk
M Quirk
M Chapman
(resigned
1 February 2024
)

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on
15 September 2025
and signed on behalf of the board by:
H Mehmet-Quirk
Director
Omnia Health Group Limited
Income Statement
Year ended
31 December 2024
Year to 31 Dec 2024Period from 6 Oct 2022 to 31 Dec 2023
££
Turnover
31,537
 
5,200
 
Gross profit
31,537
 
5,200
 
Administrative expenses
(158,557
 )
(428,767
 )
Operating loss
(127,020
 )
(423,567
 )
Income from shares in group undertakings
(65
 ) -  
Interest payable and similar expenses
(5
 )
(283
 )
Loss before tax
(127,090
 )
(423,850
 )
Tax on loss -   -  
Loss for the financial year
(127,090
 )
(423,850
 )
The company has no other recognised items of income or expense other than the results for the year as set out above.
Omnia Health Group Limited
Statement of Financial Position
31 December 2024
20242023
Note££
Fixed assets    
Tangible assets 5
1,513
 
3,158
 
Investments 6
5,780
 
4,700
 
7,293
 
7,858
 
Current assets    
Debtors 7
625,057
 
423,331
 
Cash at bank and in hand
2,011
 
306
 
627,068
 
423,637
 
Creditors: amounts falling due within one year 8
(1,184,301
 )
(854,345
 )
Net current liabilities
(557,233
 )
(430,708
 )
Total assets less current liabilities (549,940 ) (422,850 )
Capital and reserves    
Called up share capital
1,000
 
1,000
 
Profit and loss account
(550,940
 )
(423,850
 )
Shareholders deficit
(549,940
 )
(422,850
 )
For the year ending
31 December 2024
, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
  • The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
  • The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These
financial statements
have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
These
financial statements
were approved by the board of directors and authorised for issue on
15 September 2025
, and are signed on behalf of the board by:
H Mehmet-Quirk
Director
Company registration number:
14402315
Omnia Health Group Limited
Statement of Changes in Equity
Year ended
31 December 2024
Called up share capitalProfit and loss accountTotal
£££
At 6 October 2022 -   -   -  
Loss for the period- (423,850)(423,850)
Total comprehensive income for the period- 
(423,850
)
(423,850
)
Issue of shares
1,000
 - 
1,000
 
Total investments by and distributions to owners
1,000
 - 
1,000
 
At 31 December 2023 and 
1 January 2024
1,000
 
(423,850
)
(422,850
)
Loss for the year- (127,090)(127,090)
Total comprehensive income for the year- 
(127,090
)
(127,090
)
At
31 December 2024
1,000
 
(550,940
)
(549,940
)
Omnia Health Group Limited
Notes to the Financial Statements
Year ended
31 December 2024

1 General information

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is
2nd Floor 10 Charles Ii Street
,
London
,
SW1Y 4AA
, England.

2 Statement of compliance

These
financial statements
have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable to the UK and Republic of Ireland'.

3 Accounting policies

Basis of preparation

The
financial statements
have been prepared on the historical cost basis, as modified by the revaluation of certain assets.
The
financial statements
are prepared in sterling, which is the functional currency of the company.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Tangible assets

Tangible assets are initially measured at cost, and are subsequently measured at cost less any accumulated depreciation and accumulated impairment losses or at a revalued amount.
Any tangible assets carried at a revalued amount are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
An increase in the carrying amount of an asset as a result of a revaluation is recognised in other comprehensive income and accumulated in capital and reserves. However, the increase is recognised in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves. If a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess is recognised in profit or loss.
Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:
Office equipment
33% straight line

Fixed asset investments

Investments in subsidiaries, associates and joint ventures accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses.
Investments in subsidiaries, associates and joint ventures accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income or profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted.
Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Other fixed asset investments which are listed are measured at fair value with changes in fair value being recognised in profit or loss.
All other Investments held as fixed assets are initially recorded at cost, and are subsequently stated at cost less any accumulated impairment losses.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price and are subsequently measured as follows: Debt instruments are subsequently measured at amortised cost and commitments to receive a loan and to make a loan to another entity are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.
All other financial instruments, including derivatives, are initially recognised at fair value, which is normally the transaction price and are subsequently measured at fair value, with any changes recognised in profit or loss.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.
All equity instruments regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.
Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution pension plan

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

4 Average number of employees

The average number of persons employed by the company during the year was
1
(2023:
2.00
).

5 Tangible assets

Plant and machinery etc.
£
Cost  
At
1 January 2024
and
31 December 2024
4,732
 
Depreciation  
At
1 January 2024
1,574
 
Charge
1,645
 
At
31 December 2024
3,219
 
Carrying amount  
At
31 December 2024
1,513
 
At 31 December 2023
3,158
 

6 Investments

Shares in group undertakings and participating interests
£
Cost  
At
1 January 2024
4,700
 
Additions
1,145
 
Disposals
(65
 )
At
31 December 2024
5,780
 
Impairment  
At
1 January 2024
and
31 December 2024
 -  
Carrying amount  
At
31 December 2024
5,780
 
At 31 December 2023
4,700
 

Investments held at valuation

In respect of fixed asset investments held at valuation, the comparable amounts that would have been recognised if the assets had been carried under the historical cost model are as follows:
20242023
Shares in group undertakings and participating interestsShares in group undertakings and participating interests
££
Aggregate historical cost 5,780   4,700  
Carrying amount 5,780   4,700  

7 Debtors

20242023
££
Trade debtors
2,055
 
4,000
 
Amounts owed by group undertakings and undertakings in which the company has a participating interest
622,672
 
419,039
 
Other debtors
330
 
292
 
625,057
 
423,331
 

8 Creditors: amounts falling due within one year

20242023
££
Trade creditors
16,548
 
1,900
 
Amounts owed to group undertakings and undertakings in which the company has a participating interest
1,092,027
 
845,855
 
Taxation and social security
12,295
 
3,096
 
Other creditors
63,431
 
3,494
 
1,184,301
 
854,345